Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide.

Piano S, Singh V, Caraceni P, Maiwall R, Alessandria C, Fernandez J, Soares EC, Kim DJ, Kim SE, Marino M, Vorobioff J, de Cassia Ribeiro Barea R, Merli M, Elkrief L, Vargas V, Krag A, Singh SP, Lesmana LA, Toledo C, Marciano S, Verhelst X, Wong F, Intagliata N, Rabinowich L, Colombato L, Kim SG, Gerbes A, Durand F, Roblero JP, Bhamidimarri KR, Boyer TD, Maevskaya M, Fassio E, Kim HS, Hwang JS, Gines P, Gadano A, Sarin SK, Angeli P; International Club of Ascites Global Study Group.

Gastroenterology. 2018 Dec 12. pii: S0016-5085(18)35402-7. doi: 10.1053/j.gastro.2018.12.005. [Epub ahead of print]

PMID:
30552895
2.

Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.

Sanyal AJ, Boyer TD, Frederick RT, Wong F, Rossaro L, Araya V, Vargas HE, Reddy KR, Pappas SC, Teuber P, Escalante S, Jamil K.

Aliment Pharmacol Ther. 2017 Jun;45(11):1390-1402. doi: 10.1111/apt.14052. Epub 2017 Mar 29.

3.

Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.

Wong F, Pappas SC, Boyer TD, Sanyal AJ, Bajaj JS, Escalante S, Jamil K; REVERSE Investigators.

Clin Gastroenterol Hepatol. 2017 Feb;15(2):266-272.e1. doi: 10.1016/j.cgh.2016.07.016. Epub 2016 Jul 25.

PMID:
27464593
4.

Vanishing Bile Duct Syndrome with Hemophagocytic Lymphohistiocytosis After Minimal Change Disease.

Tey KR, Barrett K, Jain R, Boyer TD, Desai A.

Am J Med. 2016 Dec;129(12):e315-e319. doi: 10.1016/j.amjmed.2016.05.029. Epub 2016 Jun 15. No abstract available.

PMID:
27316571
5.

Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.

Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O'Leary JG, Ganger D, Jamil K, Pappas SC; REVERSE Study Investigators.

Gastroenterology. 2016 Jun;150(7):1579-1589.e2. doi: 10.1053/j.gastro.2016.02.026. Epub 2016 Feb 16.

PMID:
26896734
6.

Reply to "Points to be considered when using transient elastography for diagnosis of portal hypertension according to the Baveno's VI consensus".

Berzigotti A, Boyer TD, Castéra L, de Franchis R, Genescà J, Pinzani M.

J Hepatol. 2015 Oct;63(4):1049-50. doi: 10.1016/j.jhep.2015.07.012. Epub 2015 Jul 23. No abstract available.

PMID:
26212027
7.

A Phase II Randomized, Controlled Trial of S-Adenosylmethionine in Reducing Serum α-Fetoprotein in Patients with Hepatitis C Cirrhosis and Elevated AFP.

Morgan TR, Osann K, Bottiglieri T, Pimstone N, Hoefs JC, Hu KQ, Hassanein T, Boyer TD, Kong L, Chen WP, Richmond E, Gonzalez R, Rodriguez LM, Meyskens FL.

Cancer Prev Res (Phila). 2015 Sep;8(9):864-72. doi: 10.1158/1940-6207.CAPR-15-0029. Epub 2015 Jun 30.

8.

Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.

Angeli P, Ginès P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, Jalan R, Sarin SK, Piano S, Moore K, Lee SS, Durand F, Salerno F, Caraceni P, Kim WR, Arroyo V, Garcia-Tsao G.

J Hepatol. 2015 Apr;62(4):968-74. doi: 10.1016/j.jhep.2014.12.029. Epub 2015 Jan 28. No abstract available. Erratum in: J Hepatol. 2015 Jul;63(1):290.

9.

Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites.

Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, Jalan R, Sarin SK, Piano S, Moore K, Lee SS, Durand F, Salerno F, Caraceni P, Kim WR, Arroyo V, Garcia-Tsao G; International Club of Ascites.

Gut. 2015 Apr;64(4):531-7. doi: 10.1136/gutjnl-2014-308874. Epub 2015 Jan 28. No abstract available.

PMID:
25631669
10.

Big spleens and hypersplenism: fix it or forget it?

Boyer TD, Habib S.

Liver Int. 2015 May;35(5):1492-8. doi: 10.1111/liv.12702. Epub 2014 Nov 7. Review.

PMID:
25312770
11.

Successful treatment of hepatitis B and C: don't forget the liver!!!

Boyer TD, Habib S.

Am J Med. 2015 Jan;128(1):3-4. doi: 10.1016/j.amjmed.2014.09.008. Epub 2014 Sep 19. No abstract available.

PMID:
25242231
12.

Use of sirolimus in the treatment of refractory autoimmune hepatitis.

Chatrath H, Allen L, Boyer TD.

Am J Med. 2014 Nov;127(11):1128-31. doi: 10.1016/j.amjmed.2014.06.016. Epub 2014 Jun 27.

PMID:
24979741
13.

Use of noninvasive markers of portal hypertension and timing of screening endoscopy for gastroesophageal varices in patients with chronic liver disease.

Berzigotti A, Bosch J, Boyer TD.

Hepatology. 2014 Feb;59(2):729-31. doi: 10.1002/hep.26652. Epub 2013 Dec 24. No abstract available.

PMID:
23913844
14.

Reversal of severe hepatitis with infliximab in adult-onset Still's disease.

Singh B, Biboa J, Musuku S, Patel C, Pugh JL, Boyer TD.

Am J Med. 2013 Feb;126(2):e3-4. doi: 10.1016/j.amjmed.2012.08.003. No abstract available.

PMID:
23331455
15.

The search for the holy grail: doing more with less.

Boyer TD.

Am J Med. 2012 Dec;125(12):1147-8. doi: 10.1016/j.amjmed.2012.05.022. Epub 2012 Oct 3. No abstract available.

PMID:
23040788
16.

Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.

Habib S, Boyer TD.

Therap Adv Gastroenterol. 2012 May;5(3):189-97. doi: 10.1177/1756283X12437357.

17.

Endoscopic ultrasound with biopsy of omental mass for cholangiocarcinoma diagnosis in cirrhosis.

Rial NS, Gilchrist KB, Henderson JT, Bhattacharyya AK, Boyer TD, Nadir A, Cunningham JT.

World J Gastrointest Endosc. 2011 Jun 16;3(6):124-8. doi: 10.4253/wjge.v3.i6.124.

18.

Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1.

Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P; Terlipressin Study Group.

Liver Transpl. 2011 Nov;17(11):1328-32. doi: 10.1002/lt.22395.

19.

Constitutional telomerase mutations are genetic risk factors for cirrhosis.

Calado RT, Brudno J, Mehta P, Kovacs JJ, Wu C, Zago MA, Chanock SJ, Boyer TD, Young NS.

Hepatology. 2011 May;53(5):1600-7. doi: 10.1002/hep.24173.

20.

Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics.

Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, Teuber P; Terlipressin Study Group.

J Hepatol. 2011 Aug;55(2):315-21. doi: 10.1016/j.jhep.2010.11.020. Epub 2010 Dec 15.

21.

Management of refractory ascites and hepatorenal syndrome.

Sussman AN, Boyer TD.

Curr Gastroenterol Rep. 2011 Feb;13(1):17-25. doi: 10.1007/s11894-010-0156-6.

PMID:
21080246
22.

Tolvaptan and hyponatremia in a patient with cirrhosis.

Boyer TD.

Hepatology. 2010 Feb;51(2):699-702. doi: 10.1002/hep.23522. No abstract available.

PMID:
20101750
23.

The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009.

Boyer TD, Haskal ZJ; American Association for the Study of Liver Diseases.

Hepatology. 2010 Jan;51(1):306. doi: 10.1002/hep.23383. No abstract available.

PMID:
19902484
24.

Management of portal vein thrombosis.

Boyer TD.

Gastroenterol Hepatol (N Y). 2008 Oct;4(10):699-700. No abstract available.

25.

Alcohol consumption by cirrhotic subjects: patterns of use and effects on liver function.

Lucey MR, Connor JT, Boyer TD, Henderson JM, Rikkers LF; DIVERT Study Group.

Am J Gastroenterol. 2008 Jul;103(7):1698-706. doi: 10.1111/j.1572-0241.2008.01837.x. Epub 2008 May 20.

PMID:
18494835
26.
27.

Transjugular intrahepatic portosystemic shunt (TIPS): its time has come.

Boyer TD.

J Clin Gastroenterol. 2008 May-Jun;42(5):437-8. doi: 10.1097/MCG.0b013e31815f5ad8. No abstract available.

PMID:
18344898
28.

Cost of preventing variceal rebleeding with transjugular intrahepatic portal systemic shunt and distal splenorenal shunt.

Boyer TD, Henderson JM, Heerey AM, Arrigain S, Konig V, Connor J, Abu-Elmagd K, Galloway J, Rikkers LF, Jeffers L; DIVERT Study Group.

J Hepatol. 2008 Mar;48(3):407-14. Epub 2007 Oct 23.

29.

Clinical trials for variceal bleeding: and the winner is--the patient.

Boyer TD.

Liver Transpl. 2007 Sep;13(9):1212-3. No abstract available.

30.

Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States.

Peters MG, Di Bisceglie AM, Kowdley KV, Flye NL, Luketic VA, Munoz SJ, Garcia-Tsao G, Boyer TD, Lake JR, Bonacini M, Combes B; PUMPS Group.

Hepatology. 2007 Sep;46(3):769-75.

31.

Distal splenorenal shunt versus transjugular intrahepatic portal systematic shunt for variceal bleeding: a randomized trial.

Henderson JM, Boyer TD, Kutner MH, Galloway JR, Rikkers LF, Jeffers LJ, Abu-Elmagd K, Connor J; DIVERT Study Group.

Gastroenterology. 2006 May;130(6):1643-51.

PMID:
16697728
32.

Wedged hepatic vein pressure (WHVP): ready for prime time.

Boyer TD.

Hepatology. 2006 Mar;43(3):405-6. No abstract available.

PMID:
16496346
34.

Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.

Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo MJ, McCashland TM, Zetterman RK, Peters MG, Di Bisceglie AM, Benner KG, Kowdley KV, Carithers RL Jr, Rosoff L Jr, Garcia-Tsao G, Boyer JL, Boyer TD, Martinez EJ, Bass NM, Lake JR, Barnes DS, Bonacini M, Lindsay KL, Mills AS, Markin RS, Rubin R, West AB, Wheeler DE, Contos MJ, Hofmann AF.

Hepatology. 2005 Nov;42(5):1184-93.

PMID:
16250039
36.

Primary prophylaxis for variceal bleeding: are we there yet?

Boyer TD.

Gastroenterology. 2005 Apr;128(4):1120-2. Review. No abstract available.

PMID:
15825093
37.

Primary prophylaxis against variceal bleeding: beta-blockers, endoscopic ligation, or both?

Chalasani N, Boyer TD.

Am J Gastroenterol. 2005 Apr;100(4):805-7.

PMID:
15784022
38.

The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension.

Boyer TD, Haskal ZJ; American Association for the Study of Liver Diseases.

Hepatology. 2005 Feb;41(2):386-400. Review. No abstract available.

PMID:
15660434
40.

Screening in liver disease: report of an AASLD clinical workshop.

Adams PC, Arthur MJ, Boyer TD, DeLeve LD, Di Bisceglie AM, Hall M, Levin TR, Provenzale D, Seeff L.

Hepatology. 2004 May;39(5):1204-12. Review.

PMID:
15122748
41.

Changing clinical practice with measurements of portal pressure.

Boyer TD.

Hepatology. 2004 Feb;39(2):283-5. Review. No abstract available.

PMID:
14767977
43.

Transjugular intrahepatic portosystemic shunt: current status.

Boyer TD.

Gastroenterology. 2003 May;124(6):1700-10. Review.

PMID:
12761727
44.
45.

Autoimmune hepatitis in African Americans: presenting features and response to therapy.

Lim KN, Casanova RL, Boyer TD, Bruno CJ.

Am J Gastroenterol. 2001 Dec;96(12):3390-4.

PMID:
11774954
46.

Pharmacologic treatment of portal hypertension: past, present, and future.

Boyer TD.

Hepatology. 2001 Oct;34(4 Pt 1):834-9. Review. No abstract available.

PMID:
11584383
47.

Serum hyaluronic acid in patients with veno-occlusive disease following bone marrow transplantation.

Fried MW, Duncan A, Soroka S, Connaghan DG, Farrand A, Peter J, Strauss RM, Boyer TD, McDonald GB.

Bone Marrow Transplant. 2001 Mar;27(6):635-9.

48.

Management of variceal bleeding.

Boyer TD.

Indian J Gastroenterol. 2001 Mar;20 Suppl 1:C97-9. Review. No abstract available.

PMID:
11293192
49.

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.

Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, Fried MW, Purdum PP 3rd, Jensen D, Smith C, Lee WM, Boyer TD, Lin A, Pedder S, DePamphilis J.

Hepatology. 2001 Feb;33(2):433-8.

PMID:
11172346
50.

Differential lobular induction in rat liver of glutathione S-transferase A1/A2 by phenobarbital.

Selim N, Branum GD, Liu X, Whalen R, Boyer TD.

Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G542-50.

Supplemental Content

Loading ...
Support Center